drugset
drugset / Trial / NCT03850873

A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics

NCT03850873 ↗

Phase 1 Completed 40 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

TQB3616 may work in cancer by stopping cancer cells from multiplying.TQB3616 is in a new class of drugs called CDK inhibitors.This research study is the first time that TQB3616 will be given to people.TQB3616 is taken by mouth daily.

Timeline

Start
2019-05-20
Primary completion
2021-09-23
Completion
2021-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject TQB3616 Small molecule 20 unknown Oral
Subject TQB3616 Small molecule 40 mg Oral
Subject TQB3616 Small molecule 60 mg Oral
Subject TQB3616 Small molecule 80 mg Oral
Subject TQB3616 Small molecule 100 mg Oral
Subject TQB3616 Small molecule 120 mg Oral

Indications

breast cancer